Quantitative Western blot analysis of plasma ADAMTS13 antigen in patients with Upshaw-Schulman syndrome
Authors:
- Hideo YagiHYHideo Yagi
- Masanori MatsumotoMMMasanori Matsumoto
- Kenji SoejimaKSKenji Soejima
- Tomohiro NakagakiTNTomohiro Nakagaki
- Yoshihiro FujimuraYFYoshihiro Fujimura
- 1 January 2007
- journal article
- research article
- Published by Elsevier in Thrombosis Research
- Vol. 120 (3) , 381-386
Abstract
No abstract availableThis publication has 22 references indexed in Scilit:
- Novel monoclonal antibody‐based enzyme immunoassay for determining plasma levels of ADAMTS13 activityTransfusion, 2006
- Analysis on the Molecular Species and Concentration of Circulating ADAMTS13 in BloodThe Journal of Biochemistry, 2006
- Relation between ADAMTS13 activity and ADAMTS13 antigen levels in healthy donors and patients with thrombotic microangiopathies (TMA)Thrombosis and Haemostasis, 2006
- Identification of novel mutations in ADAMTS13 in an adult patient with congenital thrombotic thrombocytopenic purpuraBlood, 2004
- VWF73, a region from D1596 to R1668 of von Willebrand factor, provides a minimal substrate for ADAMTS-13Blood, 2004
- Molecular characterization of ADAMTS13 gene mutations in Japanese patients with Upshaw-Schulman syndromeBlood, 2003
- ADAMTS13 gene mutation in congenital thrombotic thrombocytopenic purpura with previously reported normal VWF cleaving protease activityBlood, 2003
- von Willebrand factor cleaving protease and ADAMTS13mutations in childhood TTPBlood, 2003
- Congenital Deficiency of a Factor in Normal Plasma That Reverses Microangiopathic Hemolysis and ThrombocytopeniaNew England Journal of Medicine, 1978
- THROMBOTIC THROMBOCYTOPENIC PURPURAMedicine, 1966